Dabigatran etexilate - Boehringer Ingelheim
Alternative Names: BIBR 953; BIBR 953 ZW; BIBR-1048; BIBR-1048MS; Dabigatran; Dabigatran etexilate mesilate; Dabigatran etexilate mesylate; Dabigatran etexilate methanesulfonate; Pradax; Pradaxa; Pradaxar; PrazaxaLatest Information Update: 30 Dec 2021
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Population Health Research Institute
- Class Amines; Antiarrhythmics; Anticoagulants; Antihaemorrhagics; Antithrombotics; Benzimidazoles; Carboxylic acids; Cardiovascular therapies; Esters; Pyridines; Small molecules; Vascular disorder therapies
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Phase III Cardiomyopathies; Cardiovascular disorders; Gastrointestinal haemorrhage; Vascular disorders
- Discontinued Acute coronary syndromes
Most Recent Events
- 30 Dec 2021 Efficacy and safety data from phase IIb/III DIVERSITY trial in Venous thromboembolism presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)
- 21 Jun 2021 Registered for Venous thromboembolism (In adolescents, In children) in USA (PO, Capsule)
- 21 Jun 2021 Registered for Venous thromboembolism (In children, In infants, Prevention) in USA (PO, Pellet)